Dishman Carbogen Amcis Intrinsic Value
DCAL • Healthcare
Current Stock Price
₹162.01
Primary Intrinsic Value
₹366.08
Market Cap
₹502.2 Cr
+126.0%
Upside
Median Value
₹366.08
Value Range
₹107 - ₹486
Assessment
Trading Below Calculated Value
Safety Margin
55.7%
DCAL Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹366.08 | ₹292.86 - ₹439.30 | +126.0% | EPS: ₹16.64, Sector P/E: 22x |
| Book Value Method | asset | ₹405.02 | ₹364.52 - ₹445.52 | +150.0% | Book Value/Share: ₹1881.29, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹324.02 | ₹291.62 - ₹356.42 | +100.0% | Revenue/Share: ₹852.90, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹324.02 | ₹291.62 - ₹356.42 | +100.0% | EBITDA: ₹628.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹405.02 | ₹324.02 - ₹486.02 | +150.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹106.50 | ₹95.85 - ₹117.15 | -34.3% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹257.09 | ₹231.38 - ₹282.80 | +58.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹486.03 | ₹437.43 - ₹534.63 | +200.0% | EPS: ₹16.64, BVPS: ₹1881.29 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
DCAL Intrinsic Value Analysis
What is the intrinsic value of DCAL?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Dishman Carbogen Amcis (DCAL) is ₹366.08 (median value). With the current market price of ₹162.01, this represents a +126.0% variance from our estimated fair value.
The valuation range spans from ₹106.50 to ₹486.03, indicating ₹106.50 - ₹486.03.
Is DCAL undervalued or overvalued?
Based on our multi-method analysis, Dishman Carbogen Amcis (DCAL) appears to be trading below calculated value by approximately 126.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.98 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 4.5% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 23.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.26x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Dishman Carbogen Amcis
Additional stock information and data for DCAL
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹375 Cr | ₹277 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹379 Cr | ₹267 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹266 Cr | ₹19 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹355 Cr | ₹46 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹513 Cr | ₹323 Cr | Positive Free Cash Flow | 8/10 |